ASH: Reduced-Dose Anticoagulants Not Noninferior for Recurrent VTE
By Elana Gotkine HealthDay Reporter
FRIDAY, Dec. 6, 2024 -- Noninferiority of reduced- versus full-dose anticoagulants cannot be proven in patients with venous thromboembolism who need extended anticoagulation, according to a study to be presented at the annual meeting of the American Society of Hematology, held from Dec. 7 to 10 in San Diego.
Francis Couturaud, M.D., Ph.D., from the University of Brest in France, and colleagues conducted a multicenter, prospective, randomized trial comparing extended anticoagulation with reduced-dose versus full-dose direct oral anticoagulants in patients with venous thromboembolism at high risk for recurrence, who were initially treated for six to 24 months.
The researchers found that recurrent venous thromboembolism occurred in 19 of 1,383 patients in the reduced-dose group versus 15 of 1,385 in the full-dose group during the 36-month median follow-up (five-year cumulative incidence, 2.2 versus 1.8 percent; hazard ratio, 1.32; 95 percent confidence interval, 0.67 to 2.60; P = 0.23 for noninferiority). Clinically relevant bleeding occurred in 96 patients in the reduced-dose group and 154 in the full-dose group (five-year cumulative incidence, 9.9 versus 15.2 percent). The composite outcome of recurrent venous thromboembolism and clinically relevant bleeding occurred in 113 and 166 patients in the reduced- and full-dose groups, respectively (five-year cumulative incidence, 11.8 versus 16.5 percent). All-cause death occurred in 4.3 and 6.1 percent of patients in the reduced- and full-dose groups, respectively.
"The noninferiority of a reduced-dose versus a full-dose of direct anticoagulants to prevent recurrent venous thromboembolism could not be proven," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Most Patients Newly Diagnosed With A-Fib Do Not Receive Anticoagulants
WEDNESDAY, April 23, 2025 -- For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed anticoagulants in the year...
Venous Thromboembolism Risk Higher for Certain Hormonal Contraceptives
THURSDAY, Feb. 13, 2025 -- Venous thromboembolism (VTE) risk varies across hormonal contraceptives, according to a research letter published online Feb. 10 in the Journal of the...
Bleeding Risks for Oral Anticoagulants and Aspirin Mostly Similar
TUESDAY, Feb. 11, 2025 -- Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rates are higher for rivaroxaban...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.